A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir.

ABSTRACT: A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

SUBMITTER: Ramirez-Sanchez C 

PROVIDER: S-EPMC9679803 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature